High expression of TROP2 correlates with poor prognosis in pancreatic cancer

D Fong, P Moser, C Krammel, J M Gostner, R Margreiter, M Mitterer, G Gastl, G Spizzo, D Fong, P Moser, C Krammel, J M Gostner, R Margreiter, M Mitterer, G Gastl, G Spizzo

Abstract

Pancreatic cancer is one of the most devastating human malignancies. Despite considerable research efforts, it remains resistant to almost all available treatment regimens. The human trophoblast cell-surface antigen, TROP2, was found to be strongly expressed in a variety of human epithelial cancers, correlating with aggressiveness and poor prognosis. TROP2 antigen expression was investigated retrospectively by immunohistochemistry in paraffin-embedded primary tumour tissue samples from a series (n=197) of consecutive patients with pancreatic adenocarcinoma. Survival was calculated using Kaplan-Meier curves. Parameters found to be of prognostic significance in univariate analysis were verified in a multivariate Cox regression model. TROP2 overexpression was observed in 109 (55%) of 197 pancreatic cancer patients and was significantly associated with decreased overall survival (P<0.01). By univariate analysis, TROP2 overexpression was found to correlate with the presence of lymph node metastasis (P=0.04) and tumour grade (P=0.01). Furthermore, in the subgroup of patients treated surgically with curative intent, TROP2 overexpression significantly correlated with poor progression-free survival (P<0.01). Multivariate analyses revealed TROP2 to be an independent prognosticator. These findings suggest for the first time that TROP2 could be a novel prognostic biomarker for pancreatic cancer. Targeting TROP2 might be a useful treatment approach for patients with pancreatic cancer overexpressing this cell-surface marker.

Figures

Figure 1
Figure 1
TROP2 immunostaining in pancreatic tissue, original magnification × 100. (A) TROP2-negative tumour sample (score 0), normal pancreatic tissue (arrow) showing weak (score 2) immunostaining. Pancreatic ductal adenocarcinoma with moderate (score 6) (B) and strong (score 12) (C and D) TROP2 expression, note the TROP2-negative islets of Langerhans (arrow).
Figure 2
Figure 2
Prognostic significance of TROP2 antigen expression in 197 patients with pancreatic ductal adenocarcinomas regarding overall survival as calculated by Kaplan–Meier analysis. Low, patients with tumour (n=88) without TROP2 overexpression; high, patients with tumour (n=109) with TROP2 overexpression. Patients with low TROP2 expression had significantly better overall survival than patients with high TROP2 expression as defined by the log-rank test (P<0.01).
Figure 3
Figure 3
Prognostic significance of TROP2 antigen expression in the subgroup of patients who underwent surgery with curative intent regarding overall (n=134) and progression-free (n=105) survival as calculated by Kaplan–Meier analysis. Patients with tumour tissue presenting TROP2 overexpression (TROP2 high) had a significant shortened overall survival (A) and progression-free (B) interval as compared with patients with tumours lacking TROP2 overexpression (TROP2 low).

References

    1. Basu A, Goldenberg DM, Stein R (1995) The epithelial/carcinoma antigen EGP-1, recognized by monoclonal antibody RS7-3G11, is phosphorylated on serine 303. Int J Cancer 62: 472–479
    1. de Bono JS, Tolcher AW, Forero A, Vanhove GF, Takimoto C, Bauer RJ, Hammond LA, Patnaik A, White ML, Shen S, Khazaeli MB, Rowinsky EK, LoBuglio AF (2004) ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas. Clin Cancer Res 10: 7555–7565
    1. Fong D, Spizzo G, Gostner JM, Gastl G, Moser P, Krammel C, Gerhard S, Rasse M, Laimer K (2008) TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol 21: 186–191
    1. Fornaro M, Dell'Arciprete R, Stella M, Bucci C, Nutini M, Capri MG, Alberti S (1995) Cloning of the gene encoding Trop-2, a cell-surface glycoprotein expressed by human carcinomas. Int J Cancer 62: 610–618
    1. Fradet Y, Cordon-Cardo C, Thomson T, Daly ME, Whitmore Jr WF, Lloyd KO, Melamed MR, Old LJ (1984) Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies. Proc Natl Acad Sci USA 81: 224–228
    1. Gastl G, Spizzo G, Obrist P, Dunser M, Mikuz G (2000) Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 356: 1981–1982
    1. Govindan SV, Stein R, Qu Z, Chen S, Andrews P, Ma H, Hansen HJ, Griffiths GL, Horak ID, Goldenberg DM (2004) Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel. Breast Cancer Res Treat 84: 173–182
    1. Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL, van Heek T, Ashfaq R, Meyer R, Walter K, Berg K, Hollingsworth MA, Cameron JL, Yeo CJ, Kern SE, Goggins M, Hruban RH (2002) Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol 160: 1239–1249
    1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55: 10–30
    1. Linnenbach AJ, Seng BA, Wu S, Robbins S, Scollon M, Pyrc JJ, Druck T, Huebner K (1993) Retroposition in a family of carcinoma-associated antigen genes. Mol Cell Biol 13: 1507–1515
    1. Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO (1994) Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 125: 437–446
    1. Nakashima K, Shimada H, Ochiai T, Kuboshima M, Kuroiwa N, Okazumi S, Matsubara H, Nomura F, Takiguchi M, Hiwasa T (2004) Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Int J Cancer 112: 1029–1035
    1. Ohmachi T, Tanaka F, Mimori K, Inoue H, Yanaga K, Mori M (2006) Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res 12: 3057–3063
    1. Riethmuller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Funke I, Pichlmaier H, Hirche H, Buggisch P, Witte J, Pichlmayr R (1998) Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 16: 1788–1794
    1. Ripani E, Sacchetti A, Corda D, Alberti S (1998) Human Trop-2 is a tumor-associated calcium signal transducer. Int J Cancer 76: 671–676
    1. Ruan HH, Scott KR, Bautista E, Ammons WS (2003) ING-1(heMAb), a monoclonal antibody to epithelial cell adhesion molecule, inhibits tumor metastases in a murine cancer model. Neoplasia 5: 489–494
    1. Schon MP, Schon M, Mattes MJ, Stein R, Weber L, Alberti S, Klein CE (1993) Biochemical and immunological characterization of the human carcinoma-associated antigen MH 99/KS 1/4. Int J Cancer 55: 988–995
    1. Shih LB, Xuan H, Aninipot R, Stein R, Goldenberg DM (1995) In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer. Cancer Res 55: 5857s–5863s
    1. Sobin LH, Fleming ID (1997) TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 80: 1803–1804
    1. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD (2000) Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4: 567–579
    1. Stein R, Basu A, Chen S, Shih LB, Goldenberg DM (1993a) Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody. Int J Cancer 55: 938–946
    1. Stein R, Govindan SV, Mattes MJ, Chen S, Reed L, Newsome G, McBride BJ, Griffiths GL, Hansen HJ, Goldenberg DM (2003b) Improved iodine radiolabels for monoclonal antibody therapy. Cancer Res 63: 111–118
    1. Stein R, Govindan SV, Mattes MJ, Shih LB, Griffiths GL, Hansen HJ, Goldenberg DM (1999c) Targeting human cancer xenografts with monoclonal antibodies labeled using radioiodinated, diethylenetriaminepentaacetic acid-appended peptides. Clin Cancer Res 5: 3079s–3087s
    1. Stoecklein NH, Siegmund A, Scheunemann P, Luebke AM, Erbersdobler A, Verde PE, Eisenberger CF, Peiper M, Rehders A, Esch JS, Knoefel WT, Hosch SB (2006) Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker. BMC Cancer 6: 165.
    1. Terrinoni A, Dell'Arciprete R, Fornaro M, Stella M, Alberti S (2001) Cyclin D1 gene contains a cryptic promoter that is functional in human cancer cells. Genes Chromosomes Cancer 31: 209–220
    1. Varga M, Obrist P, Schneeberger S, Muhlmann G, Felgel-Farnholz C, Fong D, Zitt M, Brunhuber T, Schafer G, Gastl G, Spizzo G (2004) Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res 10: 3131–3136
    1. Velders MP, van Rhijn CM, Oskam E, Fleuren GJ, Warnaar SO, Litvinov SV (1998) The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas. Br J Cancer 78: 478–483
    1. Villablanca EJ, Renucci A, Sapede D, Lec V, Soubiran F, Sandoval PC, Dambly-Chaudiere C, Ghysen A, Allende ML (2006) Control of cell migration in the zebrafish lateral line: implication of the gene ‘Tumour-Associated Calcium Signal Transducer,’ tacstd. Dev Dyn 235: 1578–1588
    1. Wang J, Day R, Dong Y, Weintraub SJ, Michel L (2008) Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther 7: 280–285
    1. Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, Hruban RH, Ord SE, Sauter PK, Coleman J, Zahurak ML, Grochow LB, Abrams RA (1997) Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 226: 248–257
    1. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B, Kinzler KW (1997) Gene expression profiles in normal and cancer cells. Science 276: 1268–1272

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren